IMA 970A
Alternative Names: Cancer Vaccine - HEPAVAC; Hepatocellular carcinoma vaccine - HapaVaC; HepaVac-101 vaccine; IMA 970 ALatest Information Update: 31 Jan 2024
At a glance
- Originator Fondazione IRCCS Istituto Nazionale dei Tumori; immatics biotechnologies GmbH; University of Insurbia; University of Tubingen
- Developer CureVac; Immatics N.V.; National Cancer Institute, Naples
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 22 Nov 2022 Immatics N.V. in collaboration with National Cancer Institute, Naples initiates a phase I trial in Liver cancer (Combination therapy, Second-line therapy or greater) in Italy (NCT06218511)
- 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
- 20 Dec 2019 immatics biotechnologies and CureVac completes a phase I/II trial in Liver cancer (Combination therapy, Second-line therapy or greater) in Germany, Spain, Belgium, Italy and United Kingdom (NCT03203005) (EudraCT2015-003389-10)